The Statistical Core supports the Projects by providing the data management and analytical services described in the Aims below. Broadly, our goals are to facilitate and ensure accuracy, cost efficiency and appropriate interpretation in the achievement of the scientific aims from each Project. Statistical Core leader Dr. Amalia Magaret has 9 years of experience planning and analyzing studies of herperviruses as well as designing derivative statistical methodology. Data manager Stacy Selke developed the data management procedures which have facilitated collection, quality assurance and sharing of laboratory and clinical data between POI Projects and Cores for 25 years. In the recent cycle. Dr. Joshua Schiffer has developed mathematical models deepening our understanding of the mechanisms influencing viral shedding and the role of the host immune response in containing the virus in the mucosa. Our team is integral to the scientific aims of this POI through our familiarity with the large store of data amassed by our clinic, our established relationships, and our collective experience in HSV research.
Our aims are:
Aim 1 : Consult in the design of experimental methods, including sample size computation, and the conceptualization of Viral dynamics studies.
Aim 2 : Coordinate data management, overseeing data collection procedures, laboratory sample management, results handling and integration of diverse data sources.
Aim 3 : Perform appropriate statistical analyses and modeling, contributing to the interpretation and reporting of results.
Aim 4 : Design novel dynamical mathematical models and other statistical methodologies as needed, optimizing our analytic approach.

Public Health Relevance

The Statistical Core assists all Projects by helping the investigators plan, carry out and analyze their findings using appropriate methods. Our contribution helps ensure that the Specific Aims of each Project include the correct number of participants and samples, and that the subsequent scientific evidence is represented, interpreted and disseminated accurately

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-LR-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Washington
United States
Zip Code
Posavad, C M; Zhao, L; Mueller, D E et al. (2015) Persistence of mucosal T-cell responses to herpes simplex virus type 2 in the female genital tract. Mucosal Immunol 8:115-26
Melvin, Ann J; Mohan, Kathleen M; Schiffer, Joshua T et al. (2015) Plasma and cerebrospinal fluid herpes simplex virus levels at diagnosis and outcome of neonatal infection. J Pediatr 166:827-33
Perti, Tara; Nyati, Mandisa; Gray, Glenda et al. (2014) Frequent genital HSV-2 shedding among women during labor in Soweto, South Africa. Infect Dis Obstet Gynecol 2014:258291
Dhankani, Varsha; Kutz, J Nathan; Schiffer, Joshua T (2014) Herpes simplex virus-2 genital tract shedding is not predictable over months or years in infected persons. PLoS Comput Biol 10:e1003922
Gantt, Soren; Cattamanchi, Ashok; Krantz, Elizabeth et al. (2014) Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy. J Clin Virol 60:127-32
Johnston, Christine; Zhu, Jia; Jing, Lichen et al. (2014) Virologic and immunologic evidence of multifocal genital herpes simplex virus 2 infection. J Virol 88:4921-31
Slyker, Jennifer; Farquhar, Carey; Atkinson, Claire et al. (2014) Compartmentalized cytomegalovirus replication and transmission in the setting of maternal HIV-1 infection. Clin Infect Dis 58:564-72
Delaney, Shani; Gardella, Carolyn; Saracino, Misty et al. (2014) Seroprevalence of herpes simplex virus type 1 and 2 among pregnant women, 1989-2010. JAMA 312:746-8
Phipps, Warren; Saracino, Misty; Selke, Stacy et al. (2014) Oral HHV-8 replication among women in Mombasa, Kenya. J Med Virol 86:1759-65
Mark, Karen E; Spruance, Spotswood; Kinghorn, George R et al. (2014) Three phase III randomized controlled trials of topical resiquimod 0.01-percent gel to reduce anogenital herpes recurrences. Antimicrob Agents Chemother 58:5016-23

Showing the most recent 10 out of 270 publications